Key facts
- DNA Script’s last known valuation is $659.7M (Jan 2022).
- It has raised $298.7M across 1 recorded rounds; the latest was Later Stage VC (Series C) ($191.7M) in Jan 2022.
- Notable investors include Bpifrance, Fidelity Management & Research Company, European Commission, Coatue Management, La French Tech — 34 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 34 names
- ·Watchlist + deal alerts for DNA Script
Funding rounds
1 roundsAbout DNA Script
Developer of DNA printer technology designed to print synthetic nucleic acids for genomics and molecular biology applications. The company's technology features a novel biochemical process for nucleic acid synthesis based on the use of efficient enzymes to provide rapid production of important genomic experimental precursors, such as an oligonucleotide, enabling researchers to accelerate their experiments and development of new therapeutics.
- Industry
- Biotechnology
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2014
- Employees
- 142
- Website
- dnascript.com/
- Ownership
- Privately Held (backing)
DNA Script doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in DNA Script shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on DNA Script in its N-PORT filings yet. We sweep new filings monthly.